AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 281 min read$NEO

NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates

NeoGenomics reported Q3 2026 revenue of $209.3M, beating estimates by 1.1%. Adjusted EPS was $0.07, a 26.2% beat. Adjusted EBITDA was $18.67M, an 17.9% beat. The company raised full-year revenue guidance to $808M and adjusted EPS to $0.22, with EBITDA guidance at $60M, above estimates.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$NEOBullishMed
01

Why it matters

The earnings beat and raised guidance could attract new buying interest and support the stock price in the short term.

02

Market read

First report of NeoGenomics' Q3 earnings and guidance, providing fresh data for traders.

03

What to watch

Potential headwinds from reimbursement policy changes could temper upside.

Relevance 7/10Novelty 8/10Timing: post‑market release

Background

NeoGenomics (NASDAQ:NEO) is a molecular diagnostics company that provides cancer testing services.

Company-level read

Ticker impact

$NEOBullishHigh confidence
Context

NeoGenomics reported Q3 2026 results beating revenue and EPS estimates and raised full-year guidance.

Expected impact

likely pressure to the upside as the market prices in the beat and higher guidance

Evidence & confidence

Both top-line and EPS beat, plus upward revision of full-year targets, typically drive buying interest.

Market effects

Sector

Positive for the molecular diagnostics sector as NeoGenomics shows demand growth.

Regional

Limited to U.S. biotech investors.

Global

Minor, confined to niche biotech space.

Counterpoint

What could challenge this read

If guidance still falls short of analyst expectations, the beat may be priced out quickly.

Key entities

  • company
    NeoGenomics

    Molecular diagnostics firm reporting Q3 2026 results.

Read at source← All news

Related articles

OCT 28
$NEOMed

NeoGenomics Reports Third Quarter 2026 Results

NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeoGenomics Reports Third Quarter 2026 Results Total revenue increased 11% YoY to $209 million Clinical services revenue grew 13%, with NGS revenue growth of 29% Company raises full-year 2026 revenue and adjusted EBITDA guidance Fort Myers, Florida (October 28, 2026)

SEC EDGAR 8-K2 min
OCT 7
$NEOMed

Piper Sandler reiterates Neogenomics stock rating on service strength

Piper Sandler reiterated an Overweight rating on Neogenomics (NEO), citing its competitive position in the community oncology lab market. The firm highlighted the company's service and menu offerings, with NEO ranking first in menu completeness, turnaround, and service. NEO's stock has fallen 10% to $16.42, despite an 83% return over the past year. Recent earnings exceeded expectations, with adjusted earnings of $0.05 per share and revenue of $202 million.

investing.com2 min